Home > Formulary : Adult > Recent Decisions > 2022 >
Decisions 15th March 2022
At the meeting on the 15th March, the following decisions were agreed
New Drug Requests
Approved
Acetylcholine (TLS Red)
-
For assessment of microvascular angina, restricted to Bristol Heart Institute only
Mifepristone (oral) (TLS Red)
-
For medical management of miscarriage, followed by Misopristol
Sucralfate liquid (oral) (TLS Red)
-
For treatment of oral mucositis for oncology and haematology patients
Acarizax (oral) (TLS Red)
-
For adolescents and adults with severe rhinitis or house dust mite allergic asthma
Shared Care Protocols/ TLS Status Changes
-
Safinamide changed from TLS Red to TLS Amber 3 months SCP and SCP approved
Updated SCPs
-
Prasugrel updated SCP
Other Formulary Decisions
-
Covid Medicines: Tocilizumab, Sarilumab, Remdesivir, Casirivimab/ imdevimab to be included on the Joint Formulary as TLS Red
-
Removal of concise DMARD sheets for azathioprine, leflunomide, methorexate, penicillamine
-
Dapagliflozin removed from BNSSG Formulary for type 1 diabetes, as dapagliflozin is no longer licensed for this indication. NICE TA 597 has been withdrawn
-
Adult Blood and Nutrition chapter Review. As part of the review the following changes were made to the formulary:
- addition of individual trace elements for TPN bags
- further information regarding nutritional supplements for metabolic disorders and other indications not explicitly covered by the formulary
-layout change for the vitamin page
Further Work
Utrogestan vaginal capsules
-
The Joint Formulary Group approved utrogestan vaginal capsules for the treatment of women with a history of at least one previous miscarriage, with an intrauterine pregnancy confirmed by ultrasound scan with symptoms of vaginal bleeding as TLS red in line with NICE NG 126 guideline recommendation once internal Trust financial approval has been given. Therefore utrogestan vaginal capsules for this indication remain non-formulary until internal financial approval has been agreed.
Melatonin
Work across the BNSSG system is taking place over the next year to review existing and proposed indications for inclusion to the formulary. Further information will be available following discussion of these applications at Joint Formulary Group meetings (expected to discuss September 2022 and December 2022).